Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial

BACKGROUND: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive urothelial carcinoma. However, the efficacy and safety of adjuvant nivolumab in Japanese patients with muscle-invasive urothelial c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Kobayashi, Ko, Kimura, Go, Oya, Mototsugu, Uemura, Hirotsugu, Nishiyama, Hiroyuki, Galsky, Matthew D, Nasroulah, Federico, Collette, Sandra, Broughton, Edward, Ünsal-Kaçmaz, Keziban, Kamisuki, Yukinori, Bajorin, Dean F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825712/
https://www.ncbi.nlm.nih.gov/pubmed/36300304
http://dx.doi.org/10.1093/jjco/hyac155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825712/
https://www.ncbi.nlm.nih.gov/pubmed/36300304
http://dx.doi.org/10.1093/jjco/hyac155

Ejemplares similares